About the conference

The two-day conference was entirely dedicated to bringing together the latest advances, challenges and opportunities for developing medicinal products and medicinal devices for paediatric use.

The preconference workshops focussing on "Introduction to developmental and paediatric pharmaclogy" and "Introduction to Regulatory Framework and PIP Quality Sections" helped to maximise the learning experience by a specialist in the topic area.

Moving on to the plenary sessions with the focus on 'Patient-centricity: synergies between paediatric and geriatric medicines?' provided differences and communalities between pediatrics and geriatrics, learned the different angles and efforts taken to tackle 'Schistosomiasis-a Most Neglected Tropical Disease', a session on 'Biopharmaceutical evaluation of developmental product' highlighted the questions if we can extrapolate the data obtained in adults and if can we predict the in vivo performance of developmental products based on in vitro data?. Further the need and risks associated with mixing the products with food and approaches to mitigate these risks were presented. Further interesting presentations included European survey on paediatric medicine administration devices: experiences and opinions of healthcare professionals, Quality considerations of PIPs for monoclonal antibodies: a regulatory perspective, The applicability of cell based systems in the prediction of taste for pharmaceutical products and many more. An Innovation Show Case gave an opportunity for companies to present less traditional yet relevant technologies for children medicines.

The vibrant poster session with many selected by peer review for oral presentation provided an overview of the current practices and challenges in the aforementioned areas, to illustrate specific remedies utilized by paediatric drug development teams to overcome hurdles.

The conference enabled participants to present, discuss breakthroughs and expand their knowledge on recent developments and challenges in the area of paediatric medicines and administration devices, from academia, industry, hospitals, and regulatory authorities. It brought together international leaders in the fields of paediatric formulation development to discuss emerging topics in these areas.

We invite you to note the dates of 7^th EuPFI conference in your diary and begin planning your participation, as well as your abstract submissions.

Conference Proceedings

EuPFI 2014 Abstracts

EuPFI 2014 Highlights

EuPFI 2014 Gallery

IJP Special section papers on Formulating Better medicines for Children – European Paediatric Formulation Initiative (EuPFI) 2014

Programme

EuPFI 2014 full Programme Click here

Sign up to our mailing list here and we will send you an email when the programme is online and keep visiting the website for conference updates in the meanwhile.

Abstract submission for EuPFI 2014 is now open only for posters

Abstracts should only be submitted via the online submission links below. Please note, abstracts submitted via email or fax will not be accepted. Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

The presenting author is expected to attend the conference and present the poster, or oral presentation. Therefore, registration and payment for the conference are pre-requisite for presenting authors.

Abstracts may be in one of the following topics:

Developing paediatric drug formulations
Pharmaceutical Excipients
Taste Masking and Taste Testing
Administration Devices
Extemporaneous and Industry Verified Preparations
Age Appropriateness of Formulation/ Compliance-Adherence Issues
Formulating Paediatric Medicines for Developing Countries
Lessons Learned from PIP Submissions.

To submit your abstract please CLICK HERE and follow the step-by-step instructions.

FORMAT

Given that the abstracts will be posted on EuPFI website exactly in the form they are submitted, authors are kindly requested to adhere to the following guidelines:

Language: English
Abstract text word limit: 300 words
Line spacing of the text: Single
Abstract title typed in UPPER CASE
The abstract should be divided into the following subsections, the subtitles should be typed in lower case:
- Introduction
- Purpose
- Materials and Methods
- Results
- Conclusions
The text may include standard abbreviations, tables, diagrams and photographs; as long as they stay within the page margins and that the total amount of words does not exceed the above mentioned limit (300 words). The 300 words limit does not include the abstract title and the names and/or affiliations of authors.

Please note that the EuPFI Conference Committee will review all submitted abstracts and decide as to the form of presentation (oral or poster) as well as the topic the abstract will be presented under. However you are encouraged to give your preference.

The 10 best abstracts will be presented as oral presentations during the conference (all other abstracts will be presented as posters).

IMPORTANT NOTES

Abstracts submitted after June 5^th, 2014 will not be accepted.
The submitting author will receive a confirmation via e-mail upon completion of abstract submission. In the event that you do not receive such notification, please contact the Conference Organisers (admin@eupfi.org).
Abstracts previously published (in local or international journals) or presented at international meetings and/or conferences, will not be accepted.
Submitting authors will be informed about the status of the abstract (accepted / rejected), by June 30^th, 2014.
Please follow the instructions carefully, as incomplete submissions will not be reviewed.
Instructions for preparation of posters and oral presentations will be sent together with the acceptance notification.

ABSTRACT WITHDRAWAL

If you wish to withdraw an abstract, please contact the Conference Organisers before June 15^th, 2014, otherwise the papers will be posted on the Conference website.

Please contact the Conference Organisers at admin@eupfi.org for any enquiries related to abstract submissions.

Abstract submissions deadline: June 15^th, 2014

Registration Guidelines

All participants are kindly recommended to register via Online Registration Form on APV website. Please fax this document to APV Headquarters: 0049 6131 9769-69 or send it via email to apv@apv-mainz.de. Please read the instructions on the APV website carefully.

To benefit from the reduced early registration fee, please process your registration before July 15^th, 2014.

Upon submitting the Registration Form, You will receive a confirmation by e-mail of your registration with the invoice.

All participants are kindly requested to register in advance by completing and submitting the Registration Form with the appropriate fees.

Registration fees

Please note unpaid pre-registration will not be considered as a valid registration unless fully paid and confirmed. Pre-registration summary therefore cannot be taken as a valid registration confirmation. Please make sure to pay your registration fee within the time frame for early or regular registration.

Students have to submit a copy of their student ID to the Conference email/contact address or fax number. Please note that if we do not receive this certification within 7 days after your data submission your registration will not be considered as valid.

*Early Bird Deadline is 15th July 2014

Delegate registration fee includes

Admission to scientific sessions, exhibition and poster area
Conference materials
Coffee breaks
Lunches
Conference Dinner & Social Programme

Insurance

The registration fees do not include insurance of participants against accidents, sickness, cancellation, theft, property damage or loss. Participants are advised to take out adequate personal insurance.

Confirmation

Upon receipt of the correct registration fee (clear of bank charges), each participant will receive a confirmation of registration. Please bring this confirmation to the Registration desk at the conference venue as proof of your registration. Confirmation will be sent upon receipt of payment.

Payment

All fees for the Conference registration should be paid in EUR (€), free of all bank charges.

Payment options

credit card payment (Visa, Eurocard/Mastercard)
by bank transfer

Cancellation / Refund Policy

We would like to point out that participation can be cancelled free of charge within two weeks of registration via the web.

Publication in the list of participants

In case you wish not to include your name and email address in the list of participants please send email to the Conference secretariat.

Responsibility

The participant acknowledges that he/she has no right to lodge damage claims against the organisers should the holding of the Conference be hindered or prevented by unexpected political or economic events or generally by force majeure, or should the non-appearance of speakers or other reasons necessitate programme changes. With registration, the participant accepts this proviso.

Accomodation Information

Official Conference Hotel

Titania Hotel Panepistimiou 52 10678 Athens

Workshops Presentation

Workshop 1: Introduction to developmental pharmacology

Opening Presentation
Hannah Batchelor, PhD, University of Birmingham, Birmingham, UK Prof. Jörg Breitkreutz, PhD, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Introduction to developmental pharmacology
Janko Samardzic, PhD, MD, University of Belgrade ,Medical Faculty, Institute of Pharmacology, Belgrade, Serbia.

Workshop 2: Introduction to Paediatric regulatory framework

Siri Wang, PhD, Norwegian Medicines Agency, Oslo, Norway

Plenary Presentation

Patient-centricity: synergies between paediatric and geriatric medicines?

Sven Stegemann, Capsugel, Belgium

Innovative partnership for a pediatric schistosomiasis treatment - a forgotten disease of forgotten people

Sonja Skopp, PhD, Merck KGaA, Germany

Biopharmaceutical evaluation of developmental products

Prof. Sandra Klein, PhD, University Greifswald, Germany

Drug dosage forms and food mixing

Terry Ernest, PhD, GlaxoSmithKline, United Kingdom

Milk as a medium for paediatric formulations: experimental findings and regulatory aspects

Prof. Panos Macheras, PhD, University of Athens, Greece

European survey on paediatric medicine administration devices: experiences and opinions of healthcare professionals

Jenny Walsh, PhD, Jenny Walsh Consulting Ltd., United Kingdom and Herbert Wachtel, PhD, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Quality considerations of PIPs for monoclonal antibodies: a regulatory perspective

Nasir Hussain, MHRA, VRMM Division, London, United Kingdom

The applicability of cell based systems in the prediction of taste for pharmaceutical products

Afzal Mohamed, PhD, Aston University, Aston, United Kingdom

Acceptability testing of minitablets from neonates to pre-school children

Viviane Klingmann, Children’s University Hospital, Düsseldorf, Germany

Formulation factors affecting acceptability of medicines in children and older adults

Fang Liu, PhD, University of Hertfordshire, United Kingdom

Adverse drug reactions associated with unlicensed medicines in children: a nested case-control study of paediatric inpatients

Jennifer R Bellis, Alder Hey Children’s NHS Foundation Trust, UK

PK simulation of the impact of manipulation of desmopressin on subsequent clinical exposure in children with diabetes insipidus

Hannah Batchelor, PhD, University of Birmingham, UK

Development and Usability of the STEP (Safety and Toxicity of Excipients for Paediatrics) database

Smita Salunke, UCL School of Pharmacy, United Kingdom

Pediatric medicines for neglected tropical diseases: development of praziquantel fast-dissolving granules

Ramona Trastullo Department of Pharmacy and BioTechnology, University of Bologna, Italy

Development of a continuous manufacturing process for double-layer orodispersible films containing cardiovascular drugs for children

Yasmin Thabet, Heinrich-Heine-University of Düsseldorf, Germany

Development of taste masked micropellets for paediatric use

Annette Grave, PhD, Glatt Pharmaceutical Services, Germany

Innovation Showcase Presentations

TAIN – A collaborative approach to met paediatric patient needs in a rare disease

Daniela Kauzor, Norbert Poellinger, PhD, Glatt, Germany

X-Straw – Dose Sipping Technology

Elke Sternberger-Rützel, PhD, DS Technology, Harro Höfliger, Germany

Patient-centric Pediatric Drug Formulation Principles: Case Studies from Aptalis Pharmaceutical Technologies

Mauro Serratoni, PhD, Aptalis Pharma S.r.l., Italy

Paediatric focussed Liquid Dosing Devices

Gero Eichelkraut, RAUMEDIC AG, Germany

Administration Devices

#8 Medication ErrorsIn Neonatal Units And Strategies To Avoid Them: A Review Of The Literature.

Elena Santesteban, Ainara Campino, and Adolfo Valls I Soler

#22 Immediate-Release Carbamazepine FormulationFor Individually Dosing By The Solid Dosage Pen

Eva Julia Laukamp, Markus Thommes, and Joerg Breitkreutz

#25 Age-Specific In Vitro Investigations Using A Single Dose Dry Powder Inhaler

Sandra Lindert

#43 Predictability Of The Extrathoracic And Pulmonary Deposition Using An Idealized Pediatric Mouth-Throat Model

Antje Below, Deborah Bickmann, and Joerg Breitkreutz

#49 Performance Study OfA Nasal Product

Deborah Bickmann

Developing Age Appropriate Formulations/ Compliance-Adherence Issues

#2 Influence Of Thickening Agents On The Properties Of Orodispersible Drug-Free Polymer Films

Christina Woertz and Peter Kleinebudde

#10 How To Determine Suitable Mechanical Strength Of Orodispersible Fiilms?

Maren Preis and Jörg Breitkreutz

#14 In Vitro In Vivo Correlation (Ivivc) For Paracetmol And Caffeine In Timpediatric Simulating Gi Conditions Of (Pre-Term) Neonates, Infants And Toddlers

Bart Anneveld, Jeroen Bongers, Saskia N. de Wildt, Barbara A. de Koning, Mark L. Huijsman, Miriam G. Mooij, Sieto Bosgra, Lidwien M. Hanff, Wouter Vaes, and Rob Havenaar

#15 ProspectiveWork On Developing Paediatric Drug Formulations For Neuropediatric Department In A French University Hospital

Roger, Damien Lannoy, Elodie Simon, Hélène Beaussart, Christophe Berneron, Louis Vallée, and Pascal Odou

#19 DevelopmentOf A Paediatric Oral Solution Of Bilastine

E. Beascoa, I. Artaiz, E. Corta, I. Justo, C. Pumar, L. González, L. Díez, I. Bueno, And A. Gonzalo

#21 Pediatric Oral FormulationsFor Valsartan And Candesartan

Malgorzata Sznitowska, Katarzyna Centkowska, Katarzyna Hoppe, Anna Kluk, Eliza Wolska, and Monika Musko

#26 Development Of Fast Dispersible Tablets Of Cobicistat

Joanna Koziara and Lei Hong

#29 Three PossibilitiesFor Solubilizing Lorazepam In A Pediatric Oral Liquid Formulation

Iris van der Velde, Lidwien Hanff, Andras Vermes, Birgit Koch, Oscar Smeets, Doerine Postma, and Arnold Vulto

#30 Development Of A Pediatric Amlodipine Solution For Oral Use

Iris van der Velde, Lidwien Hanff, Andras Vermes, Birgit Koch, Oscar Smeets, Doerine Postma, and Arnold Vulto

#32 DevelopmentOf Buccal Films As Novel Dosage Form For Paediatric Use

Ramona Trastullo, Valentina Ragazzini, Angela Abruzzo, Barbara Luppi, Teresa Cerchiara, and Federica Bigucci

#33 Pharmaceutical Industry Approaches To the Formulation DevelopmentOf Paediatric Products

Jennifer Walsh and Kevin Hughes

#34 Tablet Size AcceptabilityIn Paediatric Populations: Preliminary Data

Hannah K. Batchelor, Rebecca Venables, John Marriott, Kevin Hughes, Charlotte Miller, Heather Stirling, and Claire Callens

#36 Tacrolimus Oral Suspensions Prepared From CapsulesWith Distinct Excipients - Stability And Optimization

Joana Gomes, Paulo Lobão, and Maria Fernanda Bahia

#45 Development Of Modified Release Paediatric Liquids

Kofi Asare-Addo, Mohammed Mahdi, and Alan Mark Smith

#46 Potential Reasons ForThe Variability Of Oral Ibuprofen Pharmacokinetics In Neonates - An In Vitro Study

Elisabeth Kersten and Sandra Klein

#47 Paediatric Milk-Based Dispersible Tablets: A DesignOf Experiment Approach

Samuel Ebiowe Fanifini Orubu, Nicholas John Hobson, Anne Cram, Kate Boxell, and Catherine Tuleu

#50 Liquids Or Tablets For Children:Making The Choice

Rebecca Venables1 V, James Hodson H, Hannah B, Heather S, and John M

#51 Predicting Nasal DiscomfortWith The Slug Mucosal Irritation Test

Joke Lenoir, Ilse Claerhout, Philippe Kestelyn, Jean-Paul Remon, and Els Adriaens

#59 End-user Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 1: School Children and Adolescents

Sejal Ranmal, Celine Bilbul, Anne Cram, Catherine Tuleu

#60 End-user Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 2: Parents and Carers

Sejal Ranmal, Celine Bilbul, Anne Cram, Catherine Tuleu

Modification of Dosage Forms For Children

#6 Multiparticulate Dosage Form With Fast Disintegration for Pediatric Use – DevelopmentAnd Characterization

Huong Hoang Thi and Marie-Pierre Flament

#16 The Effect Of Food And Co-Administration On Amoxicillin Bioaccessiblity As Studied In The In Vitro Model Timpediatric

Bart Anneveld, Jeroen Bongers, Saskia N. de Wildt, Barbara A. de Koning, Miriam G. Mooij, Mark L. Huijsman, Lidwien Hanff, Wouter Vaes, and Robert Havenaar

#17 Problems With The Administration of Oral Formulations To Children: #Perspectives Of Medical Practitioners, Pharmacists And Nurses.

Rebecca Hayley Venables, Heather Stirling, and John Marriott

#18 Oral Formulation-Related Barriers to Medicines AdministrationIn Children With Chronic Conditions: Views Of Parents And Young People

Rebecca Hayley Venables, Heather Stirling, and John Marriott

#39 Importance of PolymorphismIn Paediatric Oral Liquid Pharmaceutical Compounding Of Hydrocortisone

Nora Provenza, Beatriz Clares, Mireia Mallandrich, Maria Adolfina Ruiz, and Ana Cristina Calpena

#41 Development ofAn Extemporaneous Hydroxyurea syrup For Paediatric Use

Stuart T. Charlton, Tila Balasuriya, Elisabeth Corbett, Chris Knutsen, Sharon Lamb, and Stephen Grier